Image

A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)

A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Several studies suggest that advanced multi-modal imaging with CTP should be used to screen late time window stroke patients for thrombectomy. However, NCCT is more accessible when comparing with CTP. It is unclear whether the NCCT-based ASPECTS can be used as an imaging criterion to screen patients for thrombectomy.

The newly published MR CLEAN-LATE and TENSION trials used NCCT or CTA, but still relied on ASPECTS scores to evaluate and select patients for endovascular therapy. However, different trials have different time windows. The aim of this trial was to assess the clinical outcomes of stroke patients with anterior large vessel occlusion who selected by simple imaging (NCCT) comparing via standard imaging screening strategy (CTP/MRI). The hypothesis is that simple imaging is non-inferior to standard imaging selection strategy in terms of achieving favorable outcomes.

Eligibility

Inclusion Criteria:

  1. Aged 18 years or older;
  2. The interval time from last known well to hospital arrival is within 24 hours;
  3. Acute stroke confirmed by clinical symptoms or imaging examination;
  4. Field Assessment Stroke Triage for Emergency Destination (FAST ED) ≥4;
  5. Written informed consent is obtained from patients and/or their legal representatives.

Exclusion Criteria:

  1. Allergy to radiographic contrast agents, or nitinol devices;
  2. Currently pregnant or lactating (women patients);
  3. Arterial tortuosity and/or other arterial disease that would prevent the device from reaching the target vessel;
  4. Preexisting neurological or psychiatric disease that would confound the neurological functional evaluations;
  5. Multiple vessel occlusion (e.g., bilateral anterior circulation, or occlusion of both anterior and posterior circulation);
  6. Brain tumors with mass effect (except meningiomas) that are radiographically pleasant;
  7. Intracranial aneurysm, arteriovenous malformation;
  8. Any terminal illness with life expectancy less than 6 months;
  9. Unlikely to be available for 90-day follow-up.

Study details
    Stroke
    Ischemic
    Stroke
    Acute

NCT05230914

Xinqiao Hospital of Chongqing

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.